Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Seeks Cargo Planes To Fly In Post-Brexit Medicines Supplies

Executive Summary

As preparations for a no-deal Brexit intensify, the UK government has published a tender asking for freight operators to transport medicines and other essential products to the UK, whether by air, land or sea, to “preserve human welfare”.

You may also be interested in...

Will Pharma Firms Bear Cost Of UK Govt’s Latest No-Deal Brexit Supply Plans?

Life science companies are uneasy over the government’s latest proposals for emergency medical supplies to the UK if the country leaves the EU without a deal.

UK Takes More Action To Fly In No-Deal Brexit Drug Supplies

In the latest move in its no-deal Brexit preparations, the UK is offering a contract for suppliers to provide an “uninterrupted supply of medicines and medical products,” including temperature controlled and time-sensitive medicines.

How Will You Spend Extra £434m On No-Deal Brexit Planning? Industry Asks UK Gov’t

BioIndustry Association wants more information about the UK government’s latest £2.1bn investment to fund preparations for a no-deal Brexit.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts